OncClub

>

OncClub

OncLive On Air® is a podcast from OncLive® that provides oncology professionals with the resources and information they need to provide the best patient care. Segments cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. New episodes with exclusive interviews with leading oncology experts are released on Mondays and Thursdays.

Alex F. Herrera, MD, chief, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, associate medical director, Briskin Center for Clinical Research, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope

Explore Findings With Nivolumab Plus AVD in Advanced-Stage Classic Hodgkin Lymphoma: With Alex F. Herrera, MD

Alex Herrera, MD
December 13th 2024

Dr Herrera explains why N+AVD is a strong candidate for primary treatment in adolescent and adult patients with stage III or IV Hodgkin lymphoma.

Heinz-Josef Lenz, MD, FACP, about the prognostic and predictive value of HER2 gene expression for patients with KRAS wild-type metastatic colorectal cancer (mCRC). Lenz is a professor in the Department of Medicine and the Department of Preventive Medicine in the Division of Oncology at the University of Southern California (USC) Keck School of Medicine in Los Angeles. He also serves as the associate director of Clinical Research, chair of the Gastrointestinal Oncology Program, and co-director of the Colorectal Center at the USC Norris Comprehensive Cancer Center

Lenz Discusses the Prognostic and Predictive Value of HER2 Gene Expression in KRAS Wild-Type mCRC

Heinz-Josef Lenz, MD
June 3rd 2024

Lenz discusses the link between HER2 expression and responses with mCRC treatment regimens and how HER2 expression can guide treatment decision-making.

Amin Nassar, MD, hematology/oncology fellow, Yale University; Elias Bou Farhat, MD, postdoctoral research fellow, Department of Medicine, Brigham and Women’s Hospital

Bou Farhat and Nassar on the Use of NGS Mutation Signature vs IHC for Identifying dMMR Tumors

Amin Nassar, MD;Elias Bou Farhat, MD
April 29th 2024

Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.

Michael Feigin, PhD

Feigin Discusses the Association Between Benzodiazepines and Pancreatic Cancer Outcomes

OncLive Staff
November 13th 2023

Dr Feigin discusses findings from a study on the varying effects of the benzodiazepines lorazepam and alprazolam on progression-free survival outcomes for patients with pancreatic cancer.

Jennifer M. King, MD

King Describes Unmet Needs and the Role of Surgical Resection in Residual Non-RP Testicular Cancer

OncLive Staff
July 6th 2023

Dr King discusses the need for improved guidance when determining the appropriate management strategy for patients with residual nonretroperitoneal testicular cancer and findings from a study on the association between the presence of teratoma in the primary orchiectomy and the rate of teratoma in this disease.